CHU Charles Nicolle

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Childhood cancers3 trials
• Liver and biliary tract cancer2 trials
• Myasthenia gravis2 trials
• Obesity2 trials
• Bladder cancer1 trial
• COPD1 trial
• Crohn's disease1 trial
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Melanoma1 trial
• Parkinson disease1 trial
• Sarcoma1 trial
• and 2 more

Phase

• Phase 37 trials
• Phase 22 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed7 trials
• Not yet recruiting4 trials
• Recruiting4 trials
• Suspended1 trial

Lead sponsor

• Centre Hospitalier Universitaire de Nice2 trials
• Eli Lilly and Company2 trials
• Federation Francophone de Cancerologie Digestive2 trials
• ADIR Association1 trial
• Assistance Publique - Hôpitaux de Paris1 trial
• and 8 more

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Aude MARIE-CARDINE, Dr

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

  NCT07570589· Centre Hospitalier Universitaire de Nice· Source

  Contact: Anne-Laure BEDAT-MILLET, PH

• Recruiting

  Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

  NCT07072988· Phase 4· Centre Hospitalier Universitaire de Nice· Source

  Contact: Linda Zourdani, PH

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Nicolas RICHARD (principal investigator)

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

  Contact: Frederic DI FIORE, MD

• Recruiting

  Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

  NCT05521776· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Eric VERSPYCK, Pr

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Myasthenia gravis2 recruiting
• Obesity2 recruiting
• Crohn's disease1 recruiting
• Liver and biliary tract cancer1 recruiting
• Sarcoma1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· Phase 2/3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

  NCT05361434· Ipsen· Source

• Completed

  A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

  NCT05258071· Phase 2· Integrative Research Laboratories AB· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Theravia· Source

• Completed

  A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

  NCT03635983· Phase 3· Bristol-Myers Squibb· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source